Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-75220795 in Fatty Liver Disease
NCT04844450Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2021
- Primary completion
- Mar 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ARO-PNPLA3 in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Treatment-Emergent Signs and Symptoms/ Adverse Events, Number of Participants With Change From Baseline in Vital Signs Abnormalities and 3 more. Started Apr 2021; status: completed.
02
Drugs
ARO-PNPLA3
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04844450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844450.